Pharma BD Deal Intelligence

Hansoh Pharmaceutical Group Co. Ltd. / Jiangsu Hengrui Pharmaceuticals Co. Ltd.

2025 · Licensing/Option · Complete

Hansoh Pharmaceutical Group entered a license agreement with Jiangsu Hengrui Pharmaceuticals, disclosed on 28 December 2025, for exclusive rights to develop, manufacture and commercialize SHR6508 in mainland China excluding Hong Kong, Macau and Taiwan. SHR6508 is an allosteric modulator of the calcium-sensing receptor in Phase III development for secondary hyperparathyroidism in adult chronic kidney disease patients requiring hemodialysis. Terms comprise an RMB 30 million upfront payment, up to RMB 190 million in milestones and tiered single-digit royalties on net sales. USD value not disclosed; original currency retained.

This deal is too recent to grade. Critic Score and Outcome Score are assigned after the announcement-week coverage settles and, for Outcome, after the 5-year post-close assessment window opens — expected 2030 at the earliest for this deal, once/if it closes.

Key facts

Related deals

See the full interactive analysis, sources & comparables →

← Browse all deals  ·  How we score deals

More: 2025 deals